Predictive Value of Plasma Hepatocyte Growth Factor/Scatter Factor Levels in Patients with Clinically Localized Prostate Cancer
暂无分享,去创建一个
[1] D. Kuban,et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Michael W Kattan,et al. Validating a prognostic model , 2006, Cancer.
[3] P. Kantoff,et al. Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480. , 2006, Clinical genitourinary cancer.
[4] S. Moon,et al. Expression of hepatocyte growth factor and c-Met in hypopharyngeal squamous cell carcinoma , 2006, Acta oto-laryngologica.
[5] M. Gonen,et al. Concordance probability and discriminatory power in proportional hazards regression , 2005 .
[6] Y. Fujiuchi,et al. Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer. , 2005, European urology.
[7] W. Jiang,et al. Hepatocyte growth factor/scatter factor and prostate cancer: a review. , 2005, Histology and histopathology.
[8] T. Essam,et al. Hepatocyte growth factor as a tumor marker in the serum of patients with prostate cancer. , 2005, Journal of the Egyptian National Cancer Institute.
[9] S. Sheen-Chen,et al. Serum Levels of Hepatocyte Growth Factor in Patients with Breast Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.
[10] G. Watkins,et al. Targeting the HGF/SF receptor c‐met using a hammerhead ribozyme transgene reduces in vitro invasion and migration in prostate cancer cells , 2004, The Prostate.
[11] C. Roehrborn,et al. Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy. , 2004, The Journal of urology.
[12] Michael W Kattan,et al. Evaluating a New Marker’s Predictive Contribution , 2004, Clinical Cancer Research.
[13] F. Burkhard,et al. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? , 2003, The Journal of urology.
[14] Victor Reuter,et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. , 2003, The Journal of urology.
[15] G. Watkins,et al. The HGF/SF antagonist NK4 reverses fibroblast‐ and HGF‐induced prostate tumor growth and angiogenesis in vivo , 2003, International journal of cancer.
[16] F. Wawroschek,et al. Lymph Node Staging in Clinically Localized Prostate Cancer , 2003, Urologia Internationalis.
[17] J. Reis-Filho,et al. Expression of c-met Tyrosine Kinase Receptor Is Biologically and Prognostically Relevant for Primary Cutaneous Malignant Melanomas , 2003, Oncology.
[18] Y. Skornick,et al. Detection of hepatocyte growth factor/scatter factor receptor (c-Met) in axillary drainage after operations for breast cancer using reverse transcriptase–polymerase chain reaction , 2003, Breast Cancer Research.
[19] Douglas S Scherr,et al. High expression of the Met receptor in prostate cancer metastasis to bone. , 2002, Urology.
[20] A. Heidenreich,et al. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. , 2002, The Journal of urology.
[21] K. Matsumoto,et al. The HGF/SF-induced phosphorylation of paxillin, matrix adhesion, and invasion of prostate cancer cells were suppressed by NK4, an HGF/SF variant. , 2001, Biochemical and biophysical research communications.
[22] G. V. Vande Woude,et al. Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. , 2001, The American journal of pathology.
[23] P. Humphrey,et al. Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer. , 2001, The Journal of urology.
[24] W. Jiang,et al. Cell-cell adhesion molecules and signaling intermediates and their role in the invasive potential of prostate cancer cells. , 2000, The Journal of urology.
[25] Y. Cho,et al. Significant Correlation between Serum Level of Hepatocyte Growth Factor and Progression of Gastric Carcinoma , 1999, World Journal of Surgery.
[26] M. Murata,et al. Progression-linked overexpression of c-Met in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers. , 1999, Cancer letters.
[27] M. Becich,et al. A simple method for the isolation and culture of epithelial and stromal cells from benign and neoplastic prostates. , 1997, Urology.
[28] A W Partin,et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.
[29] M W Kattan,et al. Evaluation of a Nomogram used to predict the pathologic stage of clinically localized prostate carcinoma , 1997, Cancer.
[30] L. Weissfeld,et al. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. , 1997, Cancer research.
[31] W. Catalona,et al. Longitudinal screening for prostate cancer with prostate-specific antigen. , 1996, JAMA.
[32] P. Humphrey,et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. , 1995, The American journal of pathology.
[33] P. Troncoso,et al. c-met proto-oncogene expression in benign and malignant human prostate tissues. , 1995, The Journal of urology.
[34] D. Henson,et al. Practice protocol for the examination of specimens removed from patients with carcinoma of the prostate gland. A publication of the cancer committee, college of american pathologists. Task Force on the Examination of Specimens Removed From Patients With Prostate Cancer. , 1994, Archives of pathology & laboratory medicine.
[35] M. Ogawa,et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. , 1994, Cancer research.
[36] Y. Sekido,et al. Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer , 2010 .
[37] A. Jemal,et al. Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.
[38] K. Matsumoto,et al. Involvement of hepatocyte growth factor in increased integrin expression on HepG2 cells triggered by adhesion to endothelial cells. , 1997, British Journal of Cancer.
[39] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.